不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
非 DLBCL 的单形性与霍奇金淋巴瘤 PTLD：临床见解与治疗策略
英文原题：Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.
查看英文原题
Non-DLBCL monomorphic and Hodgkin lymphoma PTLD: clinical insights and treatment strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大 B 细胞淋巴瘤（DLBCL）以外的单形性移植后淋巴增殖性疾病（PTLD）较罕见，生物学异质性较高，缺乏可指导治疗的前瞻性数据。占多数病例的 DLBCL-PTLD，通常参考前瞻性 II 期研究采用的治疗方法，包括降低免疫抑制和按风险分层的序贯免疫化疗。相比之下，Burkitt 淋巴瘤、T/NK 细胞来源 PTLD 和浆细胞样变异等非 DLBCL 亚型更少见，治疗通常借鉴免疫功能正常患者的既定治疗方案和零星病例报告。经典型霍奇金淋巴瘤 PTLD 虽不归类为单形性 PTLD，但也是另一种独特且临床重要的亚型。本综述总结这些少见 PTLD 的流行病学、临床特征、治疗策略和结局，旨在为其管理提供实用框架。
展开英文摘要原文
Monomorphic posttransplant lymphoproliferative disorders (PTLDs) beyond diffuse large B-cell lymphoma (DLBCL) are rare, biologically heterogeneous entities with limited prospective data to guide treatment. DLBCL-PTLD, which comprises most cases, is managed using approaches informed by prospective phase 2 studies, including reduction in immunosuppression and a risk-adapted sequential immunochemotherapy approach.
In contrast, non-DLBCL subtypes such as Burkitt lymphoma, PTLDs of T/NK-cell origin, and plasmacytic variants are less common and are typically treated using strategies extrapolated from established treatment algorithms used in immunocompetent patients and sporadic case reports.
Classic Hodgkin lymphoma PTLD, although not classified as monomorphic, represents another distinct and clinically relevant subtype. This review summarizes the epidemiology, clinical features, treatment strategies, and outcomes associated with these less common PTLDs, aiming to provide a practical framework for their management.
论文信息
- 作者
- Atallah-Yunes SA、Khurana A、Habermann TM
- 单位
- Division of Hematology, Mayo Clinic, Rochester, MN.United States
- 文献类型
- 综述
- 期刊
- Blood advances2025 Nov 25
- 原文标识
- PubMed 40811832 · DOI 10.1182/bloodadvances.2025016930
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →